Kaplan-Meier survival analysis showed that patients with high serum IL-5, IL-8, PDGF-BB, and VEGF-A showed significantly better survival when treated with sorafenib; moreover, high CXCL9 and TGF-α levels were also associated with better survival with borderline significance (Fig. 3a ).
← all excerpts
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
1
—
—